Danazol for Lupus Thrombocytopenia

In: Archives of Internal Medicine · 1985 · vol. 145(12) , pp. 2251 · doi:10.1001/archinte.1985.00360120123022 · PMID:4074040 · W1994606211
article OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-08

Danazol therapy increased platelet counts in three lupus thrombocytopenia patients refractory to prednisone, though two experienced a reversible maculopapular rash.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Danazol therapy was used in the treatment of three consecutive patients with lupus-associated thrombocytopenia refractory to high-dose prednisone therapy (two patients) or in whom high-dose prednisone therapy was considered contraindicated (one patient). Treatment was associated in each case with an increase in platelet count but was complicated in two of three patients by the development of a diffuse maculopapular rash that promptly resolved following discontinuation of danazol therapy. Retreatment of one patient with danazol was associated with immediate recurrence of the rash. We suggest that danazol therapy deserves further evaluation in the treatment of lupus-associated thrombocytopenia, but advise that patients be carefully monitored for rash.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (4)

References (6)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-11T03:39:08.368949+00:00
License: CC0 · commercial use OK